MD, PhD, FRCS, FEBS (MBS) Consultant Bariatric/Metabolic and General Surgeon @ImperialNHS

London, England
Joined December 2021
Patricia M Ortega retweeted
Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO
52
2,041
444
5,569
2,631,121
Patricia M Ortega retweeted
Retatrutide, the triple receptor (GLP-1, GIP, glucagon) most potent weight loss drug yet seen (w/ 28% body weight reduction), pushes the limits, introduces some risks, by @PostRowland gift link wapo.st/3PRth2W
23
54
4
259
37,611
Patricia M Ortega retweeted
Attention Bariatric trainees! Don’t miss the @bariatricBOMSS ASM ‘26 Training Day on 10th June ‘26. A dedicated day for surgical trainees covering GLP-1s, the future of surgery, careers, academic pathways, international opportunities, & practical sessions! #bomss #bariatrics
2
3
254
Patricia M Ortega retweeted
“We're not actually buying long-term #health; we're just renting weight loss.” Dariush Mozaffarian, MD, DrPH, shares his perspective while attending the #JAMASummit on Obesity. This year’s #JAMASummit convened thought leaders to address the challenges and opportunities shaping the future of #obesity treatment. Follow this space for more. ja.ma/4tKs4rX
6
8
33
7,922
Patricia M Ortega retweeted
So folks: this means that if you have obesity…. You are 38% less likely to die if you have bariatric surgery - there are no studies for GLP-1ra that show these dramatic results.
There is a 38% less likelihood of mortality with bariatric surgery than with GLP-ra treatment. #ASMBS2026 as presented by Dr Ali Arminian
7
9
1
29
9,564
Patricia M Ortega retweeted
📢Don't miss tomorrow! IFSO - @BJSAcademy Virtual Journal Club "International Consensus Position Statement on the role of Obesity Management Medications in the context of Metabolic Bariatric Surgery: Expert Guideline by IFSO" 🗓️April 23 2026 🕑1 pm CET events.teams.microsoft.com/e…
1
2
309
New online! Lifespan approaches for the prevention and management of steatotic liver disease dlvr.it/TS3HmJ
1
13
17
2,485
Patricia M Ortega retweeted
"Medicine can have extraordinary meaning. But it cannot substitute for being present in your own life." In #APieceofMyMind, a psychiatrist and residency program director reflects on an unexpected #LungCancer diagnosis. ja.ma/48OxHxC
5
257
52
579
256,247
Patricia M Ortega retweeted
Join us for the next BJS Academy Virtual Journal Club in collaboration with IFSO 🌍 📅 23 April | ⏰ 13:00–14:00 CET We’ll be discussing the international consensus on obesity management medications in the context of metabolic bariatric surgery with a presentation by Anna Carolina Batista and expert moderation from Wendy Brown and Sara Suliman events.teams.microsoft.com/e… Looking forward to an engaging discussion—see you there! #SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide #some4UGI #uppergi #esophagealcancer #gastriccancer #reflux @ISDE_net @Augishealth @roux_group @T4UGIS @SARONG_Trial @YoungIFSO #bariatricsurgery #bariatricsurgery @IfsoSecretariat
7
1
12
4,000
Patricia M Ortega retweeted
Endorsed Course: Boston Scientific & Young IFSO Endobariatric Programme! 🗓️ July 1st - 3rd 📍 Boston Scientific Ibérica, Madrid Are you a Young IFSO member working in the EMEA region (Europe, Middle East, Africa)? Apply here by April 24th ➡️forms.office.com/r/dWgC0TVBF…
2
1
4
712
Patricia M Ortega retweeted
Metabolic/bariatric surgery achieves greater weight loss and metabolic improvements than GLP-1 RAs in RCTs (<104 wks). Tirzepatide is the most potent nonsurgical option. onlinelibrary.wiley.com/doi/…
3
48
2
175
10,599
Patricia M Ortega retweeted
Metabolic surgery outperforms GLP-1 agonists in weight loss and diabetes remission; tirzepatide narrows this gap. Read more in Obesity: ow.ly/kvsT50YEKW3 #BariatricSurgery #GLP1 #ObesityResearch @lucassabatella
9
1
26
3,924
Outstanding experience at the XX Bellvitge Bariatric & Metabolic Surgery Course in Barcelona 🔥 Exceptional scientific programme with leading national & international faculty and remarkable live surgery sessions showcasing technical excellence and open discussion. Congratulations to the organising team! @hbellvitge #BariatricSurgery #MBS #Bellvitge
1
3
1
9
644
🎥Our latest Top 10 Article-of-Interest "Brief Interview" is posted on our YouTube Channel! 🤔Dr Oviedo interviews Top-10 author Dr. Lucas Sabatella about this fascinating published article. 📺Watch it here: youtu.be/s_qx5K-dAmg 🧵1/
1
3
5
722
Patricia M Ortega retweeted
Re: My skepticism regarding GLP-1 drugs for obesity Yes, these drugs are effective for some people. However, don’t get carried away yet, especially for calls for the widespread use of these drugs. I am old enough to have seen the rise and fall of: The jejuno-ileal bypass Very low calorie diets Vertical banded gastroplasty Phen-Phen Gastric bands Orlistat Each of these was greeting with substantial enthusiasm and, given enough time, failed when long-term problems became apparent. Semaglutide roared onto the scene as the cure for obesity. With time, its side effects and limitations became apparent. It took little time before a new class of drugs with multi-receptor properties were advocated as the perfect solution for obesity. The history of weight loss interventions suggests that these new drugs will also have problems and be abandoned when the next, greatest drug is promoted by Pharma. I’d like to be wrong on this, but I have been around long enough to experience this cycle repeatedly.
40
14
5
128
48,784
Patricia M Ortega retweeted
The effect of weight change on death and cardiovascular events afterRoux-en-Y gastric bypass ➡️doi.org/10.1093/bjs/znaf170 This Swedish cohort study of 25,230 patients followed for 10.6 years after Roux-en-Y gastric bypass found that weight trajectories strongly influenced outcomes 1⃣Both continued weight loss beyond the initial nadir and substantial weight regain (>50% of lost weight) were associated with significantly increased risks of major cardiovascular events and death (HRs ~1.5–1.8) 2⃣Patients with modest weight regain (0–20%) after nadir had the most favorable outcomes These findings highlight the importance of monitoring long-term weight patterns after surgery and providing extra support for high-risk trajectories Work by Erik Stenberg, Erik Näslund, Yang Cao, Johan Ottosson, Ingmar Näslund #SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @des_winter @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide #some4UGI #uppergi #esophagealcancer #gastriccancer #reflux @ISDE_net @Augishealth @roux_group @T4UGIS @SARONG_Trial
8
1
15
4,108
Parental #preconception #BMI and risk of adverse birth outcomes in 8 million parent–child triads: a nationwide population-based cohort study in China thelancet.com/journals/landi… #underweight #overweight #obesity #ChildHealth
6
3
13
1,328
Patricia M Ortega retweeted
IFSO statement@Lancet DE: Med-induced WL isn't a reason to delay bariatric surgery. Many stop meds due to cost, intolerance, or wanting a "definitive" fix. Clinicians must not wait for the predictable relapse of complications. The goal is sustained health, not temporary metrics
2
17
1
30
2,498